First-in-human Study in Healthy Subjects

Healthy Clinical Trial

Official title:

A Phase I Adaptive Dose, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT118335 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03315338
• Other study ID #: CORT118335-850
• Status: Completed
• Phase: Phase 1
• Start date: September 15, 2017
• Est. completion date: February 22, 2019

Study information

• Verified date: May 2019
• Source: Corcept Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This initial Phase I study will evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending doses of CORT118335, the effect of concomitant administration with food on exposure to CORT118335, and its pharmacological effect in healthy subjects.

Description:

This is a 5-part, single-center study of single and multiple ascending doses of CORT118335 in healthy subjects.

Parts I and 4 of the study are double-blind, randomized, placebo-controlled assessments of single-ascending doses (SAD) of CORT118335. Subjects will be enrolled sequentially into 1 of up 8 cohorts (Part 1, Cohorts A to D [Cohorts E to G have been cancelled]; Part 4, Cohorts A to D), each containing 8 subjects. Within each cohort, 6 subjects will be randomly assigned to receive a single dose of CORT118335 and 2 subjects will be randomly assigned to receive a single dose of matching placebo.

Part 2 Cohort A, food-effect, will be an open-label 2-way crossover study in one cohort of 12 subjects, randomized in a 1:1 ratio to receive a single dose of CORT118335 once after an overnight fast and once after a high-fat breakfast or the alternate sequence, over 2 study periods separated by a washout of at least 7 days/5 half-lives.

Part 2 Cohort B, PD cohort, will be a double-blind, randomized, placebo-controlled, 3-way cross-over study and will serve as proof of pharmacological effect (GR modulation) for CORT118335. Subjects will be randomized in a 1:1:1 ratio to receive placebo, and two dose levels of CORT118335 in one of three treatment sequences across 3 study periods separated by washouts of at least 7 days/5 half-lives. On each occasion, the ability of CORT118335 to ameliorate the pharmacological effects of a single dose of prednisone will be measured.

Parts 3 and 5 are double-blind, randomized, placebo-controlled assessments of multiple oral ascending doses of CORT118335. Subjects will be enrolled sequentially into 1 of up to 4 cohorts (Part 1 Cohort A [Cohorts B to D have been cancelled; Part 5 Cohorts A to C), each containing 12 subjects. Within each cohort, 9 subjects will be randomly assigned to receive CORT118335 and 3 subjects to receive matching placebo daily for 14 days.

Different formulations of CORT118335 will be used in Parts 1, 2 and 3, and in Parts 4 and 5.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 143
• Est. completion date: February 22, 2019
• Est. primary completion date: February 22, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Healthy male subjects or non-pregnant, non-lactating healthy female subjects of non-childbearing potential

• Age 18 to 60 years

• Body mass index (BMI) of 18.0 to 30.0 kg/m2

• Weight of =102 kg

• Must be willing and able to communicate and participate in the whole study

• Morning serum cortisol of 5 µg/dL to 23 µg/dL (138 nmol/L to 635 nmol/L) at screening and/or Day -1 for multiple dose cohorts

• Must provide written informed consent

• Must agree to use an adequate method of contraception

• Must agree to adhere to study restrictions

Exclusion Criteria:

• Subjects who have received any IMP in a clinical research study within the 3 months before the first dose in this study

• Subjects who are study site or Sponsor employees, or immediate family members of a study site or Sponsor employee

• Subjects who have previously been enrolled in this study

• Males who have a pregnant partner

• History of any drug or alcohol abuse in the year before the first dose in this study

• Regular alcohol consumption in male subjects >21 units per week and female subjects >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

• Current smokers and those who have smoked within the 6 months before the first dose in this study. A breath carbon monoxide reading of greater than 10 ppm at screening or on admission

• Current users of e-cigarettes and nicotine replacement products and those who have used these products within the 6 months before the first dose in this study

• Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator at screening

• Clinically significant abnormal biochemistry, hematology or urinalysis as judged by the Investigator

• Positive drugs of abuse test result at screening or on admission (amphetamines, barbiturates, benzodiazepines, cocaine, marijuana/cannabis, methadone, methamphetamine/ecstasy, morphine/opiates, phencyclidine, tricyclic antidepressants)

• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results

• Subject has active renal and/or hepatic disease, as evidenced by:

• an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m2 using Modification of Diet in Renal Disease (MDRD) equation at screening

• ALT and/or AST >1.5 times the upper limit of normal at screening or on admission

• subjects with borderline results can have these tests repeated once.

• History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, gastrointestinal or neurological disease as judged by the Investigator

• Subject had any form of cancer within the 2 years before first dose in this study*, with the exception of basal cell and/or squamous cell cancer of the skin that has been treated completely and is without evidence of local recurrence or metastasis

• Subject has a history and/or symptoms of adrenal insufficiency

• Subject has consumed liquorice or other glycyrrhetic acid derivatives regularly, in the judgement of the Investigator, in the 6 months before the first dose of study medication

• Subject has a history of jaundice and/or subject has had a cholecystectomy

• Subject has a history of clinically significant gastrointestinal disease including gastroesophageal reflux disease, malabsorption syndrome, colon cancer, chronic colitis, Crohn's disease, inflammatory bowel disease, gastroparesis, constipation, chronic diarrhoea, obstruction, gastrointestinal bleeding, and/or peptic ulcers

• Subject has a condition that could be aggravated by glucocorticoid and/or mineralocorticoid blockade (e.g., asthma, any chronic inflammatory condition) or activation (e.g., immunodeficiency, active infection)

• Subjects with inactive seasonal hay fever may be included. Subjects with childhood (aged less than 18 years) asthma may be included provided they have had no symptoms and required no treatment for at least 5 years

• Subjects with a QTcF interval of >450 msec at screening or pre-dose, based on the mean of three ECGs

• History of additional risk factors for torsades de pointes (e.g., heart failure, hypokalaemia, family history of long QT syndrome)

• Supine heart rate at rest of <40 bpm or >100 bpm. BP out with the following ranges:

diastolic BP 40-90; systolic BP 90-140 (subjects aged 18-45 year) and 90-160 (subjects aged >45 year). Heart rate and blood pressure can be retested twice in the supine position at intervals of 5 min on a given day at screening and admission.

• Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients including glucose/fructose intolerance for the standard oral glucose tolerance test (OGTT)

• Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator.

• Donation or loss of greater than 400 mL of blood within the 3 months before first study dose

• Subjects who are taking, or have taken, any prescribed, over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies within 14 days, or for which 5 times the medication's elimination half-life will not be completed if longer, before the first dose of study medication. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the Investigator and Sponsor's medical monitor. Standard dose multivitamins are permitted throughout the study period

• Subjects who are currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months or 3 months for inhaled products

• Subjects who are taking, or have taken enzyme inducers within 30 days before the first dose of study medication

• Subject is expected to require use of any medication (with the exception of standard dose multivitamins) during the study period

• Subject has a history or presence of any medical condition or disease which, in the opinion of the Investigator, could interfere with the conduct of the study or could put the subject at unacceptable risk. This specifically includes any subject with flu or flu-like symptoms

• Failure to satisfy the Investigator of fitness to participate for any other reason

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• CORT118335, 25 mg
CORT118335 is supplied as capsules for oral dosing
• Prednisone Oral Tablet
Challenge Agent, Dose and Route of Administration: Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered.
• Glucose
75 g in 300 mL solution, orally administered
• Placebo oral suspension
Reference Therapy, Dose and Route of Administration: Placebo suspension, orally administered.
• CORT118335, 75mg
CORT118335 is supplied as capsules for oral dosing
• CORT118335, 225mg
CORT118335 is supplied as capsules for oral dosing
• CORT118335, 675mg
CORT118335 is supplied as capsules for oral dosing
• CORT118335, 600mg
CORT118335 is supplied as capsules for oral dosing
• CORT118335, 630mg
CORT118335 is supplied as capsules for oral dosing
• CORT118335, 375mg
CORT118335 is supplied as capsules for oral dosing
• CORT118335, 100mg
CORT118335 is supplied as a suspension for oral dosing
• CORT118335, 300mg
CORT118335 is supplied as a suspension for oral dosing
• CORT118335, 900mg
CORT118335 is supplied as a suspension for oral dosing
• CORT118335, 150mg
CORT118335 is supplied as a suspension for oral dosing
• CORT118335, 1500mg
CORT118335 is supplied as a suspension for oral dosing
• Placebo oral capsule
Placebo capsules, orally administered
• CORT118335, dose to be determined
CORT118335 is supplied as suspension for oral dosing

Locations

Country	Name	City	State
United Kingdom	Quotient Clinical	Nottingham	Nottinghamshire

Sponsors (1)

Lead Sponsor	Collaborator
Corcept Therapeutics

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events (AEs)		SAD Cohorts: Day -28 to Day 7; Part 2A Cohorts: Day -28 to Day 14; Part 2B Cohorts: Day -28 to Day 21; MAD Cohorts: Day -28 to Day 21
Secondary	QT interval corrected for heart rate using Fridericia's formula (QTcF) exposure-response analysis		SAD parts: Pre dose through 24 hours post dose. MAD parts: Pre first dose through 24 hours post final dose of Investigational Medicinal Product (IMP
Secondary	tlag Pharmacokinetic (PK) parameter	The elapsed time from dosing at which analyte was first quantifiable in a concentration vs time profile (tlag)	SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP
Secondary	tmax PK parameter	The time from dosing at which Cmax was apparent (tmax)	SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP
Secondary	Cmax PK parameter	Maximum observed concentration (Cmax)	SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP
Secondary	tmin (MAD only) PK parameter	Time from dosing of the minimum plasma drug concentration (tmin)	MAD parts: Pre first dose through 96 hours post final dose of IMP
Secondary	Cmin (MAD only) PK parameter	Minimum plasma drug concentration (Cmin)	MAD parts: Pre first dose through 96 hours post final dose of IMP
Secondary	Clast PK parameter	Last measurable concentration (Clast)	SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP
Secondary	tlast PK parameter	Time from dosing of the last measurable concentration (tlast)	SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP
Secondary	t1/2 PK parameter	The apparent elimination half-life (t1/2)	SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP
Secondary	lambda-z PK parameter	The slope of the apparent elimination phase (lambda-z)	SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP
Secondary	AUCinf PK parameter	Area under the plasma concentration-time curve from time zero to infinity (AUCinf)	SAD parts: Pre dose through 96h post dose; MAD parts: Pre first dose through 96h post final dose of IMP
Secondary	AUC(0-last) PK parameter	Area under the curve from 0 time to last measurable concentration [AUC(0-last)]	SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP
Secondary	AUC(0-24) PK parameter	Area under the curve from 0 time to 24 h post dose [AUC(0-24)]	SAD parts: Pre dose through 24 hours post dose; MAD parts: Pre first dose through 24 hours post final dose of IMP
Secondary	Food effect: AUC(0-last) PK parameter		Pre first dose through 96 hours post final dose
Secondary	Food effect: AUC(0-inf) PK parameter	Area under the curve from 0 time extrapolated to infinity [AUC(0-inf)]	Pre first dose through 96 hours post final dose
Secondary	Food effect: Cmax PK parameter		Pre first dose through 96 hours post final dose
Secondary	Pharmacodynamics (PD): peripheral differential white blood cell count		Pre first dose through 24 hours post final dose
Secondary	PD: serum osteocalcin and adiponectin concentrations		Pre first dose through 24 hours post final dose
Secondary	PD: messenger ribonucleic acid (mRNA) expression for selected genes in whole blood		Pre first dose through 24 hours post final dose
Secondary	PD: glucose tolerance		Pre first dose through 24 hours post final dose
Secondary	Homeostatic model assessment of insulin-resistance (HOMA-IR)		Pre-dose through Day 14